Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation

Transplantation

Volumn 85, Issue 6, 2008, Pages 855-862

  Ueda, Yoshihide ^a   Takada, Yasutsugu ^a   Haga, Hironori ^a   Nabeshima, Motoshige ^a   Marusawa, Hiroyuki ^a   Ito, Takashi ^a   Egawa, Hiroto ^a   Tanaka, Koichi ^a   Uemoto, Shinji ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Biochemical response; HCV; Interferon; Living donor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; CYCLOSPORIN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PREDNISOLONE; RIBAVIRIN; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 41149123529     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181671df0     Document Type: Article

References (62)

1. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
2. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619.
3. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
4. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28.
5. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitisCvirus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250.
6. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56.
7. Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCVrecipients. Transplantation 2004; 77: 1834.
8. Brown RS Jr. Customizing treatment to patient populations. Nat Clin Pract Gastroenterol Hepatol 2007; 4(Suppl 1): S3.
9. Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006; 6: 449.
10. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005; 11: 479.
11. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1.
12. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995; 22: 1084.
13. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 1403.
14. Cattral MS, Hemming AW, Wanless IR, et al. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999; 67: 1277.
15. Gane EJ, Tibbs CJ, Ramage JK, et al. Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl Int 1995; 8: 61.
16. Berenguer M, Prieto M, Palau A, et al. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16: 1207.
17. Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283.
18. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000.
19. Giostra E, Kullak-Ublick GA, Keller W, et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004; 17: 169.
20. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181.
21. Mukherjee S, Lyden E, McCashland TM, et al. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitisCafter liver transplantation: Cohort study of 38 patients. J Gastroenterol Hepatol 2005; 20: 198.
22. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642.
23. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53.
24. Dumortier J, Scoazec JY, Chevallier P, et al. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
25. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, et al. Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 2005; 37: 2207.
26. Mukherjee S, Rogge J, Weaver L, et al. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 3042.
27. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 1303.
28. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199.
29. Bahra M, Neumann UP, Jacob D, et al. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007; 83: 351.
30. Bizollon T, Pradat P, Mabrut JY, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909.
31. Kuo A, Terrault NA. Antiviral therapy in liver transplant recipients: Is SVR the only endpoint that matters? J Hepatol 2007; 46: 359.
32. Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004; 11: 148.
33. Taniguchi H, Iwasaki Y, Fujiwara A, et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol 2006; 21: 281.
34. Ikeda K, Arase Y, Saitoh S, et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: A large-scale long-term study in a single center. Intervirology 2006; 49:82.
35. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124.
36. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94.
37. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394.
38. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30: 653.
39. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87: 741.
40. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174.
41. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780.
42. Takada Y, Haga H, Ito T, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006; 81: 350.
43. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918.
44. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877.
45. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291.
46. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatitis C: Improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004; 39: 1069.
47. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201.
48. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289.
49. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825.
50. Yoshizawa A, Takada Y, Fujimoto Y, et al. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C. Am J Transplant 2006; 6: 2812.
51. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9: 1028.
52. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699.
53. Iwai A, Marusawa H, Takada Y, et al. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection. J Viral Hepat 2006; 13: 523.
54. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308.
55. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282.
56. Fisher RA, Stone JJ, Wolfe LG, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004; 18: 463.
57. Levy G, Villamil F, Samuel D, et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 1632.
58. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial. Liver Transpl 2004; 10: 1258.
59. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517.
60. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051.
61. Ware JE, Jr., Bayliss MS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550.
62. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483.